




Surface Energy Driven Medical Device Technologies

INVESTOR PRESENTATION
Q4 2025

Privileged and Confidential





UV One Hygienics is advancing KnoxFog™, an FDA-Cleared anti-fog gel revolutionizing endoscopic visualization.

Founded in 2020, UV One Hygienics integrates surface energy engineering with advanced medical technology to pioneer breakthrough devices that address critical healthcare challenges. KnoxFog, its flagship product, offers proven clinical savings and a competitive moat through trade secrets and pending patents.

With the current funding round, seeking \$1M to \$1.5M to accelerate GMP readiness, alongside post-clearance momentum, rising demand for minimally invasive surgery, and expansion potential beyond medical (sports, vehicles, military), KnoxFog is de-risked and positioned to achieve near-term acquisition appeal with projected 3x to 5x investor ROI.



Market Opportunity



— U.S. AND GLOBAL MARKETS

OUTLOOK AND SCOPE

KnoxFog™ by UV One Hygienics delivers unmatched anti-fog performance, driving significant cost savings.

KnoxFog’s clinically validated effectiveness in laparoscopic and robotic surgeries ensures superior time savings compared to competing anti-fogging products, positioning KnoxFog as a critical innovation within the fast-growing medical devices and endoscopy markets

— U.S. MARKET

Medical Devices¹

2025	\$200.14B	2030	\$266.64B
-------------	------------------	-------------	------------------

With a CAGR of 5.9% from 2025 to 2030

Medical Technology²

2025	\$232.29B	2030	\$304.23B
-------------	------------------	-------------	------------------

With a CAGR of 5.54% from 2025 to 2030

— GLOBAL MARKET

Endoscopy Equipment³

2023	\$11.9B	2033	\$24.7B
-------------	----------------	-------------	----------------

With a CAGR of 7.6% from 2024 to 2033

1 [statista.com/outlook/hmo/medical-technology/medical-devices/united-states](https://www.statista.com/outlook/hmo/medical-technology/medical-devices/united-states)
 2 [statista.com/outlook/hmo/medical-technology/united-states](https://www.statista.com/outlook/hmo/medical-technology/united-states)
 3 [media.market.us/endoscopy-equipment-market-news/](https://www.media.market.us/endoscopy-equipment-market-news/)

Problems with Endoscope Fogging



77% of minimally invasive procedures are impacted by lens fogging each year, compromising surgeries with current solutions providing inadequate results.


ROOT CAUSE



Temperature Differences



Humidity



Bodily Fluids

KnoxFog Solution



Unparalleled Effectiveness

Delivers 30x longer clarity than competitors, ensuring over three hours of fog-free visibility during surgery

Single Application

Dip, wipe, and go – eliminates repeated disruption and saves valuable surgical time

Biocompatible and Safe

Sterile, pH-neutral, non-toxic, and food/medical safety tested with no harsh chemicals

Seamless Integration

Fully compatible with all endoscopic equipment and sterilization processes

Ease of Use

Simple, quick application requiring no maintenance, empowering surgeons with uninterrupted clarity and better patient outcomes



KnoxFog Technology and IP



KnoxFog secures its competitive moat with a dual IP strategy that leverages patents for credibility and trade secrets for perpetual protection thereby ensuring unmatched performance and market defensibility.

The core breakthrough is a biocompatible, hyper-hydrophilic gel with a proprietary natural polymer that delivers a robust, long-lasting anti-fog barrier on endoscope lenses. KnoxFog's single-dip, wipe-and-go application offers 30x longer clarity than competitors while maintaining biocompatibility, safety, and seamless integration across all surgical equipment.

This innovation is fortified by a balanced IP approach: patents accelerate market credibility while trade secrets provide indefinite protection, rapid market entry, and a sustained competitive edge. Robust security, confidentiality agreements, and strategic IP planning further mitigate risks of disclosure or misappropriation.

KNOXFOG TECHNOLOGY AND IP FORTRESS – DUAL PROTECTION STRATEGY

Core Innovation	Trade Secret Strategy	Risk Mitigation
<ul style="list-style-type: none"> Biocompatible gel with hyper-hydrophilic formulation 30x longer clarity, single application Sterile, pH neutral, non-toxic, integrates with all equipment 	<ul style="list-style-type: none"> Keeps core process and formulation undisclosed Provides perpetual protection Faster time-to-market by bypassing lengthy patent prosecution 	<ul style="list-style-type: none"> Robust security and confidentiality agreements Strategic planning to prevent parallel development Balanced patent + trade secret approach

Surface Energy Driven Medical Device Technologies

UV ONE HYGIENICS

Privileged and Confidential

OTHER TECH.

Peer Reviewed Surface Energy based Medical IP:


ClearRetina™ is a biocompatible hyper hydrophilic gel used to prevent fogging in retina surgeries in patients who have had cataract surgery.

InnovaBug, a low volume, fast and accurate handheld blood analysis unit for pathogen detection.

InnovaStrip™ is a low volume, fast, accurate, handheld comprehensive Small Volume Blood Diagnostics (SVBD) testing unit.



Leadership



Dora Suppes

CHIEF EXECUTIVE OFFICER

Dora brings more than 40 years of experience in healthcare, technology, and entrepreneurial leadership.

In 2023, she co-authored and published three scientific papers with the American Physical Society on sterilization, diagnostic devices, and anti-fog coatings, underscoring her commitment to advancing medical innovation.

Dora has a vision of making healthcare technologies both cutting-edge and accessible.



Mark Russell-Hill

CHIEF OPERATIONS OFFICER

Mark applies his deep expertise in light, optics, and engineering to drive innovation in medical device technology.

In 2023, he co-authored and published three scientific papers with the American Physical Society on sterilization, diagnostic devices, and anti-fog coatings. Mark's vision is to deliver cutting-edge medical devices that improve global healthcare access, combining entrepreneurial drive with technical innovation to position UV One as a leader in disruptive medical technologies.



Cisco Schipperheijn

CHIEF TECHNICAL OFFICER

Cisco is recognized for his strategic vision and technical expertise in developing disruptive technologies with long-term viability.

Cisco combines executive acumen with technical development to deliver predictable ROI and position UV One Hygienics as a leader in cutting-edge medical technology.

Surface Energy Driven Medical Device Technologies

UV ONE HYGIENICS

Privileged and Confidential

Leadership



Dr. Nicole Herbots
CHIEF SCIENCE OFFICER

Dr. Herbots consults on laboratory research, device design, and the transition of innovations into full-scale FDA-approved manufacturing.

Dr. Herbots has founded over a dozen medical device companies built on her patented technologies, with expertise spanning anti-fog coatings, diagnostic devices, and bio-compatible implant surfaces.



Dennis Gross
PRESIDENT / SALES

Dennis brings more than 40 years of global experience in sales, finance, and technology innovation.

His entrepreneurial drive, combined with a passion for philanthropy and service, including time in the New York National Guard and U.S. Army OCS, positions him as a critical leader guiding UV One Hygienics' growth and commercialization strategy.



Scott Harvey
VICE PRESIDENT MEDICAL SALES

Scott brings over 15 years of expertise in medical device distributorship, specializing in spine, foot and ankle, and biologics markets.

His proven track record includes consistently exceeding sales quotas, serving as Chief Commercial Officer and VP of Sales at Echelon Medical Corp., founding and leading Peritus Ortho, and acting as an independent distributor for Quest Orthopedics.

Competitive Landscape



KnoxFog outperforms costly and unreliable competitors by delivering immediate, lasting clarity without reapplication – saving hospitals up to \$24K in Operating Room time during a single 3-hour procedure.


With FDA clearance, trade secret protection, and patent filings underway, it offers 30x longer effectiveness in a simple, biocompatible solution that integrates seamlessly into surgical workflows.

	KnoxFog	FRED	CLEARIFY
	\$150 per vial with no reapplication for 3+ hours	\$20 to \$23 per use + frequent reapplication needed	\$135 per use + reapplication needed every 15 minutes
1-Hour Procedure	\$150 (1 Application)	\$60 to \$90 (3 to 4 Applications)	\$540 (4 Applications)
2-Hour Procedure	\$150 (1 Application)	\$120 to \$180 (6 to 8 Applications)	\$1,080 (8 Applications)
3-Hour Procedure	\$150 (1 Application)	\$180 to \$270 (9 to 12 Applications)	\$1,620 (12 Applications)

Key Insights

KnoxFog delivers up to 90% cost savings compared to CLEARIFY, breaking even after just over a single use. Unlike CLEARIFY, which requires costly reapplications and repeated interruptions, KnoxFog ensures uninterrupted procedures with superior efficiency and clarity.

Roadmap



Financial Projection Pre Acquisition



Minimal Traction to Trigger Acquisition

Years	Units Sold	Gross Revenue	COGS	Gross Profit	Expenses	Net Income (Pre-Tax)
0-6 months	2,000 - 5,000	\$300,000 - \$750,000	\$100,000 - \$250,000	\$200,000 - \$500,000	\$1,000,000 - \$1,500,000	(\$800,000)-(\$1,000,000)
6-12 months (YR1)	15,000-18,750	\$2250,00 - \$2812,500	\$750,000 - \$937,500	\$1,500,000 - \$1,875,000	\$900,000 - \$1,125,000	\$475,000 - \$625,000
2	Post-Acquisition Projections: Integrated into acquirer's portfolio for scaled growth.					

- o Assumptions

\$150 avg price / vial, \$50 COGS; based on pilot manufacturing/sales to achieve traction. A successful validation run of 2k-5k vials can be produced in as little as 7 -10 days. Net income is only reflective of this small run. Production will continue beyond this initial run.

- o Cost Savings Insight

Operating Room time at \$46-\$133/min; KnoxFog saves \$24K+ per 3-hr procedure.

- o Full TAM Potential

\$50M+ annual at 1% share across all medical scopes, post-acquisition.

Financial Projection



FDA-Cleared Medical Scop Anti-Fog Solution	
Market Assumptions	
Total U.S. Market (Annual Procedures)	75,000,000.00
Price per Procedure	\$ 150.00
Competitor Base Price	\$ 135.00
Competitor Total Cost (2 to 3 Applications)	\$ 270.00 – \$ 405.00
Your Cost Advantage	44% – 63%

Conservative Scenario				
Year	Market Share	Procedures	Price / Procedure	Annual Revenue
Year 1	0.25%	187,500.00	\$ 150.00	\$ 28,125,000.00
Year 2	0.75%	562,500.00	\$ 150.00	\$ 84,375,000.00
Year 3	1.50%	1,125,000.00	\$ 150.00	\$ 168,750,000.00
Year 4	2.50%	1,875,000.00	\$ 150.00	\$ 281,250,000.00
Year 5	3.50%	2,625,000.00	\$ 150.00	\$ 393,750,000.00
5-Year Total		6,375,000.00		\$ 956,250,000.00

Moderate Scenario				
Year	Market Share	Procedures	Price / Procedure	Annual Revenue
Year 1	0.50%	375,000.00	\$ 150.00	\$ 56,250,000.00
Year 2	1.50%	1,125,000.00	\$ 150.00	\$ 168,750,000.00
Year 3	3.00%	2,250,000.00	\$ 150.00	\$ 337,500,000.00
Year 4	5.00%	3,750,000.00	\$ 150.00	\$ 562,500,000.00
Year 5	7.00%	5,250,000.00	\$ 150.00	\$ 787,500,000.00
5-Year Total		12,750,000.00		\$ 1,912,500,000.00

Use of Funds



Goal


Produce a fully validated, GMP compliant, functional and scalable manufacturing process that can easily be handed over to an acquirer. Production can remain with CMO if desired.

ROI Potential

3x to 5x via acquisition; strategic fit with buyers like Medtronic / Olympus, leveraging IP and traction.


Production/Manf.(\$225K)

- CMO Set Up/GMP Compliance
- Process Validation
- Raw Materials/Inventory (2k-5k vials)




Acquisition Prep (\$300K)

- Acquisition Marketing Prep
- Acquirer Outreach (pitch materials, travel, M&A advisors)




QA/IP Protection (\$235K)

- Post Clearance QA Audits (ISO 13485,FDA, GMP)
- Third Party Testing
- Trade Secret Protection, Legal Counsel for Acquisition




Ops/Contingency (\$425K)

- Personnel & Operations
- Overhead/Insurance
- Buffer for CMO Delays, Legal Issues and Compliance Costs





Dora Suppes
CHIEF EXECUTIVE OFFICER



480-221-4712



dora@uvonetech.com



uvonetech.com/




linkedin.com/in/dora-suppes-0934439b/



UV ONE Hygienics, Inc.
Phoenix, Arizona, USA



Mark Russell-Hill
CHIEF OPERATING OFFICER



480-226-0885



mark@uvonetech.com



uvonetech.com/



linkedin.com/in/mark-russell-hill-8099998



UV ONE Hygienics, Inc.
Phoenix, Arizona, USA